Evidence map›Paper›PMID 41764665›Full record

Observational studyQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2026

Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study.

Silvana A M Urru, Flavia Mayer, Stefania Spila Alegiani, Francesca Paoloni, Anna Guella, Roberta Murru, Giampaolo Bucaneve, Giulio Formoso, Vito Racanelli, Anna Forti and 6 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Silvana A M UrruHospital Pharmacy Unit, Trento Hospital, Integrated University Health Authority of Trentino (ASUIT), Largo Medaglie d'Oro 9, 38122, Trento, Autonomous Province of Trento, Italy. silvanaannamaria.urru@apss.tn.it.ORCID http://orcid.org/0000-0001-6213-1290
Flavia MayerPharmacoepidemiology Unit, National Center for Drug Research and Evaluation, Italian National Institute of Health, 00161, Rome, Italy.
Stefania Spila AlegianiPharmacoepidemiology Unit, National Center for Drug Research and Evaluation, Italian National Institute of Health, 00161, Rome, Italy.
Francesca PaoloniFondazione GIMEMA Onlus, 00187, Rome, Italy.
Anna GuellaSection of Hematology and Stem Cell Transplantation, Department of Medicine, Trento Hospital, Integrated University Health Authority of Trentino (ASUIT), 38122, Trento, Autonomous Province of Trento, Italy.
Roberta MurruHematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, ARNAS G. Brotzu, 09134, Cagliari, Italy.
Giampaolo BucaneveOspedale S. Maria della Misericordia, 06129, Perugia, Italy.
Giulio FormosoAzienda USL-IRCCS di Reggio Emilia, 42122, Reggio Emilia, RE, Italy.
Vito RacanelliDepartment of Medicine, Trento Hospital, Integrated University Health Authority of Trentino (ASUIT), 38122, Trento, Autonomous Province of Trento, Italy.
Anna FortiDepartment of Diagnostics and Public Health, University of Verona, 37134, Verona, Italy.
Claudio FozzaDepartment of Medicine, Surgery and Pharmacy, University of Sassari, 07100, Sassari, Italy.
Giuseppe LongoOncological Medicine Unit, Azienda Ospedaliera Universitaria di Modena, 41125, Modena, Italy.
Chiara FulgenzioRegina Elena San Gallicano IRCCS di Roma, 00144, Roma, Italy.
Felice MusiccoRegina Elena San Gallicano IRCCS di Roma, 00144, Roma, Italy.
Annalisa CampomoriHospital Pharmacy Unit, Trento Hospital, Integrated University Health Authority of Trentino (ASUIT), Largo Medaglie d'Oro 9, 38122, Trento, Autonomous Province of Trento, Italy.
SURE Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvancements in treating hematologic malignancies have improved survival, but health-related quality of life (HRQoL) remains a key concern due to the physical, emotional, and social impact of disease and treatment.

aimsThis study aimed to assess HRQoL in patients undergoing treatment for hematologic malignancies, identifying the most affected domains to guide supportive interventions.

methodsHRQoL was evaluated using the 42-item Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) in a prospective, multicenter observational study on rituximab safety across Italian hematology units (March 2018-June 2022).

resultsOf 772 patients with Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL), 412 (62.6%) completed the HRQoL assessment. Overall, patients reported acceptable quality of life. Key concerns included reduced enjoyment of life (45.1%), poor sleep (42.0%), and dissatisfaction with quality of life (41.0%). Functional impairments and emotional distress were also reported. CLL patients showed slightly better physical and lymphoma-specific well-being than NHL patients. Patients with other hematologic diseases had lower scores across several domains.

conclusionsWhile HRQoL is generally acceptable in NHL and CLL, functional well-being is most impacted. Routine integration of HRQoL assessments is essential to identify unmet needs and support patient-centered care.

Indexed as

Antineoplastic Agents, ImmunologicalHematologic NeoplasmsLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-HodgkinQuality of LifeRituximabAdultAgedAged, 80 and overCross-Sectional StudiesFemaleHumansItalyMaleMiddle AgedProspective StudiesAntineoplastic Agents, ImmunologicalRituximabClinical pharmacyCross-sectional studyHematologic malignanciesQualitative researchQuality of life

Identifiers

PMID41764665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.